Literature DB >> 11357214

The treatment of epilepsy in developing countries: where do we go from here?

R A Scott1, S D Lhatoo, J W Sander.   

Abstract

Epilepsy is the most common serious neurological disorder and is one of the world's most prevalent noncommunicable diseases. As the understanding of its physical and social burden has increased it has moved higher up the world health agenda. Over four-fifths of the 50 million people with epilepsy are thought to be in developing countries; much of this condition results from preventable causes. Around 90% of people with epilepsy in developing countries are not receiving appropriate treatment. Consequently, people with epilepsy continue to be stigmatized and have a lower quality of life than people with other chronic illnesses. However, bridging the treatment gap and reducing the burden of epilepsy is not straightforward and faces many constraints. Cultural attitudes, a lack of prioritization, poor health system infrastructure, and inadequate supplies of antiepileptic drugs all conspire to hinder appropriate treatment. Nevertheless, there have been successful attempts to provide treatment, which have shown the importance of community-based approaches and also indicate that provision for sustained intervention over the long term is necessary in any treatment programme. Approaches being adopted in the demonstration projects of the Global Campaign Against Epilepsy--implemented by the International League Against Epilepsy, the International Bureau for Epilepsy, and the World Health Organization--may provide further advances. Much remains to be done but it is hoped that current efforts will lead to better treatment of people with epilepsy in developing countries.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 11357214      PMCID: PMC2566404     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  62 in total

1.  Expanding metabolism for total biosynthesis of the nonnatural amino acid L-homoalanine.

Authors:  Kechun Zhang; Han Li; Kwang Myung Cho; James C Liao
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-23       Impact factor: 11.205

2.  Attitudes towards African traditional medicine and Christian spiritual healing regarding treatment of epilepsy in a rural community of northern Tanzania.

Authors:  Andrea Sylvia Winkler; Michael Mayer; Michael Ombay; Bartholomayo Mathias; Erich Schmutzhard; Louise Jilek-Aall
Journal:  Afr J Tradit Complement Altern Med       Date:  2009-12-30

3.  Publications from Malawi, January - June 2001.

Authors:  M J Sherratt; H K Graham
Journal:  Malawi Med J       Date:  2001-09       Impact factor: 0.875

Review 4.  Epilepsy treatment in sub-Saharan Africa: closing the gap.

Authors:  J H Chin
Journal:  Afr Health Sci       Date:  2012-06       Impact factor: 0.927

5.  Epilepsy and its effects on children and families in rural Uganda.

Authors:  M B Duggan
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

6.  Global campaign against epilepsy: assessment of a demonstration project in rural China.

Authors:  Wenzhi Wang; Jianzhong Wu; Xiuying Dai; Guangyu Ma; Bin Yang; Taiping Wang; Chenglin Yuan; Ding Ding; Zhen Hong; Patrick Kwan; Gail S Bell; Leonid L Prilipko; Hanneke M de Boer; Josemir W Sander
Journal:  Bull World Health Organ       Date:  2008-12       Impact factor: 9.408

7.  Efficacy and safety of levetiracetam in pediatric epilepsy.

Authors:  Ahmed A Elberry; Rawabi K Felemban; Rawan H Hareeri; Sawsan M Kurdi
Journal:  Saudi Pharm J       Date:  2011-06-15       Impact factor: 4.330

Review 8.  The natural history of epilepsy: an epidemiological view.

Authors:  P Kwan; J W Sander
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

Review 9.  Cost of epilepsy: a systematic review.

Authors:  Adam Strzelczyk; Jens Peter Reese; Richard Dodel; Hajo M Hamer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

10.  Childhood epilepsy: Management in resource-limited setting.

Authors:  Chhaya Valvi; Subhashchandra Daga; Ujwala Kabade; Madhuri Agarwal
Journal:  Ann Indian Acad Neurol       Date:  2008-01       Impact factor: 1.383

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.